Show simple item record

dc.contributor.authorSergeant, Susan
dc.contributor.authorHallmark, Brian
dc.contributor.authorMathias, Rasika A
dc.contributor.authorMustin, Tammy L
dc.contributor.authorIvester, Priscilla
dc.contributor.authorBohannon, Maggie L
dc.contributor.authorRuczinski, Ingo
dc.contributor.authorJohnstone, Laurel
dc.contributor.authorSeeds, Michael C
dc.contributor.authorChilton, Floyd H
dc.date.accessioned2020-06-08T17:40:40Z
dc.date.available2020-06-08T17:40:40Z
dc.date.issued2020-05
dc.identifier.citationSusan Sergeant, Brian Hallmark, Rasika A Mathias, Tammy L Mustin, Priscilla Ivester, Maggie L Bohannon, Ingo Ruczinski, Laurel Johnstone, Michael C Seeds, Floyd H Chilton, Prospective clinical trial examining the impact of genetic variation in FADS1 on the metabolism of linoleic acid– and ɣ-linolenic acid–containing botanical oils, The American Journal of Clinical Nutrition, Volume 111, Issue 5, May 2020, Pages 1068–1078, https://doi.org/10.1093/ajcn/nqaa023en_US
dc.identifier.issn0002-9165
dc.identifier.pmid32167131
dc.identifier.doi10.1093/ajcn/nqaa023
dc.identifier.urihttp://hdl.handle.net/10150/641526
dc.description.abstractBackground: Unexplained heterogeneity in clinical trials has resulted in questions regarding the effectiveness of gamma-linolenic acid (GLA)-containing botanical oil supplements. This heterogeneity may be explained by genetic variation within the fatty acid desaturase (FADS) gene cluster that is associated with circulating and tissue concentrations of arachidonic acid (ARA) and dihomo-gamma-linolenic acid (DGLA), both of which may be synthesized from GLA and result in proinflammatory and anti-inflammatory metabolites, respectively. Objectives: The objective of this study was to prospectively compare the capacity of a non-Hispanic white cohort, stratified by FADS genotype at the key single-nucleoside polymorphism (SNP) rs174537, to metabolize 18-carbon omega-6 (n-6) PUFAs in borage oil (BO) and soybean oil (SO) to GLA, DGLA. and ARA. Methods: Healthy adults (n = 64) participated in a randomized, double-blind, crossover intervention. Individuals received encapsulated BO (Borago officinalis L.; 37% LA and 23% GLA) or SO [Glycine max (L.) Men.; 50% LA and 0% GLA] for 4 wk, followed by an 8-wk washout period, before consuming the opposite oil for 4 wk. Serum lipids and markers of inflammation (C-reactive protein) were assessed for both oil types at baseline and during weeks 2 and 4 of the intervention. Results: SO supplementation failed to alter circulating concentrations of any n-6 long-chain PUFAs. In contrast, a modest daily dose of BO elevated serum concentrations of GLA and DGLA in an rs174537 genotype-dependent manner. In particular, DGLA increased by 57% (95% CI: 0.38, 0.79) in GG genotype individuals, but by 141% (95% CI: 1.03. 2.85) in TiT individuals. For ARA, baseline concentrations varied substantially by genotype and increased modestly with BO supplementation, suggesting a key role for FADS variation in the balance of DGLA and ARA. Conclusions: The results of this study clearly suggest that personalized and population-based approaches considering FADS genetic variation may be necessary to optimize the design of future clinical studies with GLA-containing oils.en_US
dc.language.isoenen_US
dc.publisherOXFORD UNIV PRESSen_US
dc.rightsCopyright © The Author(s) on behalf of the American Society for Nutrition 2020.en_US
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.subjectPUFAsen_US
dc.subjectarachidonic aciden_US
dc.subjectborage oilen_US
dc.subjectgamma-linolenic aciden_US
dc.subjectgene–diet interactionen_US
dc.subjectn-3 fatty acidsen_US
dc.subjectn-6 fatty acidsen_US
dc.subjectprecision nutritionen_US
dc.subjectrandomized cross-over designen_US
dc.subjectsoybean oilen_US
dc.titleProspective clinical trial examining the impact of genetic variation in FADS1 on the metabolism of linoleic acid- and ɣ-linolenic acid-containing botanical oilsen_US
dc.typeArticleen_US
dc.identifier.eissn1938-3207
dc.contributor.departmentUniv Arizona, BIO5 Insten_US
dc.identifier.journalAMERICAN JOURNAL OF CLINICAL NUTRITIONen_US
dc.description.note12 month embargo; published online: 13 March 2020en_US
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.en_US
dc.eprint.versionFinal accepted manuscripten_US
dc.source.journaltitleThe American journal of clinical nutrition
dc.source.volume111
dc.source.issue5
dc.source.beginpage1068
dc.source.endpage1078
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Prospective_Clinical_Trial-Ser ...
Size:
271.7Kb
Format:
PDF
Description:
Final Accepted Manuscript

This item appears in the following Collection(s)

Show simple item record